JYB1904

Phase 3Small molecule

JJemincare

JYB1904 is one of 99 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic AsthmaActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Allergic AsthmaPhase 2

Active, not recruiting

Chronic Spontaneous UrticariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

REGN1908-1909

Regeneron

Phase 3

1 3

JYB1904

JJemincare

Phase 3

1 4

Allegra-D

Pfizer

Phase 3

3 5

Asmanex

Novartis

Preclinical

12 6

Veramyst

GSK

Preclinical

10 7

Singulair

AstraZeneca

Preclinical

5 8

Purethal

MMedical University of Silesia

Phase 3

1 9

Xolair

Roche

Preclinical

1 10

Bilaxten

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Chronic Spontaneous Urticaria

NCT06509334

Q2 2028

Phase 3Not yet recruiting

Chronic Spontaneous Urticaria

NCT07402213

Q4 2028

Phase 2Not yet recruiting

Allergic Rhinitis

NCT07459452

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria2 trials

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Not yet recruiting·JJemincare·Phase 3·NCT07402213·180 enrolled

Trial of JYB1904 in Chronic Spontaneous Urticaria.

Recruiting·JJemincare·Phase 2·NCT06509334·135 enrolled

Antibody1 trial

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

Completed·JJemincare·Phase 1·NCT05449535·56 enrolled

Allergic Rhinitis1 trial

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

Not yet recruiting·JJemincare·Phase 2·NCT07459452·135 enrolled

Allergic Asthma1 trial

Trial of JYB1904 in Patients With Allergic Asthma

Active, not recruiting·JJemincare·Phase 2·NCT06438757·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JYB1904. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JYB1904 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JYB1904. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jemincare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJemincare

JYB1904

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Q4 2028

Trials by Indication[1]

Chronic Spontaneous Urticaria2 trials

Antibody1 trial

Allergic Rhinitis1 trial

Allergic Asthma1 trial

References

Drug Info

Quick Facts

Related News